Primary Endpoints Not Met
- - - - -
Collaboration Under Review
CAMBRIDGE, Mass., July 30 /PRNewswire-FirstCall/ --
Biogen, Inc. (Nasdaq: BGEN) and Celltech Group plc (LSE: CCH; NYSE: CLL) today
announced that two Phase III studies of CDP 571 did not meet the primary
endpoints for patients with moderate-to-severe Crohn's disease. The companies
will review the scope of their collaboration following additional analysis of
the Phase III data and discussions with regulatory authorities.
(Photo: http://www.newscom.com/cgi-bin/prnh/19990824/BIOLOGO )
The agreement on CDP 571 between Biogen and Celltech was signed in April
2002. Biogen's continued participation is linked to assessment of the results
of these Phase III studies.
About Biogen:
Biogen, Inc., winner of the U.S. National Medal of Technology, is a
biotechnology company principally engaged in discovering and developing drugs
for human healthcare through genetic engineering. Headquartered in Cambridge,
MA, the Company's revenues are generated from U.S. and European sales of
AVONEX(R) (Interferon beta-1a) for treatment of relapsing forms of multiple
sclerosis, (please see full prescribing information at
http://www.avonex.com.), and from the worldwide sales by licensees of a number
of products, including alpha interferon and hepatitis B vaccines and
diagnostic products. Biogen's research and development activities are focused
on novel products to treat inflammatory and autoimmune diseases, neurological
diseases, cancer, fibrosis, and congestive heart failure. The Company
maintains active clinical research programs in protein therapeutics, small
molecules, genomics and gene therapy. For copies of press releases and
additional information about the Company, please consult Biogen's homepage on
the World Wide Web at http://www.biogen.com.
SOURCE Biogen, Inc.
 back to top
Related links:
http://www.biogen.com
Company News On-Call:
http://www.prnewswire.com/comp/101550.html
Photo Notes:
NewsCom:
http://www.newscom.com/cgi-bin/prnh/19990824/BIOLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, 888-776-6555 or 212-782-2840
CONTACT:
Elizabeth Woo, Director, Investor Relations,
+1-617-679-2822, or Amy McKnight, Associate Director, Public
Affairs, +1-617-679-2723, both of Biogen, Inc.
|
